United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2016_register executive 2016-08-16 article Notices D09002ee1c7f4c401 D09002ee1c7f4c505 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to practice the inventions embodied in the following Patent Applications to Circumvent Pharmaceuticals Inc. ("Circumvent") located in Pasadena, California, USA: 81 FR 54581 https://www.govinfo.gov/app/details/FR-2016-08-16/2016-19418 2016-19418 fr16au16-59 4140-01-P https://www.govinfo.gov/app/details/FR-2016-08-16/2016-19418 https://www.govinfo.gov/content/pkg/FR-2016-08-16/html/2016-19418.htm https://www.govinfo.gov/content/pkg/FR-2016-08-16/pdf/2016-19418.pdf 2 p. 54581 54582 81 FR 54581 Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Small Molecule Therapeutic Compounds Encompassed Within the Licensed Patent Rights for the Treatment of Thioesterase Deficiency Disorder; Federal Register Vol. 81, Issue NOTICE 2016-19418 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2016-08-31 4140-01-P 2016-19418 Notice.

This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to practice the inventions embodied in the following Patent Applications to Circumvent Pharmaceuticals Inc. ("Circumvent") located in Pasadena, California, USA:

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 31, 2016 will be considered. Prospective Grant of Start-up Exclusive License: Small Molecule Therapeutic Compounds Encompassed Within the Licensed Patent Rights for the Treatment of Thioesterase Deficiency Disorder , vathyams@mail.nih.gov Vol. 81, no. 158 Office of the Federal Register, National Archives and Records Administration 2016-08-16 continuing daily deposited born digital 241 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2016-08-16 P0b002ee190a68449 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr16au16 https://www.govinfo.gov/app/details/FR-2016-08-16 https://www.govinfo.gov/content/pkg/FR-2016-08-16/pdf/FR-2016-08-16.pdf https://www.govinfo.gov/content/pkg/FR-2016-08-16/xml/FR-2016-08-16.xml fdlp 54477 54707 DGPO 2016-08-16 2024-06-01 FR-2016-08-16 machine generated eng FR FR-2016-08-16 81 158